Cellular Biomedicine Group, Inc.
(NASDAQ GS: CBMG)
Rigrodsky Law, P.A. is investigating Cellular Biomedicine Group, Inc. (“CBMG”) regarding possible breaches of fiduciary duties and other violations of law related to CBMG’s agreement to be acquired by a consortium including CBMG CEO Bizuo (Tony) Liu and others. Under the terms of the agreement, CBMG’s shareholders will receive $19.75 per share in cash.